Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche Buys Oncology Diagnostics Firm
by Rick Mullin
July 25, 2011
| A version of this story appeared in
Volume 89, Issue 30
Roche has agreed to acquire MTM Laboratories, a privately held German firm that develops in vitro diagnostics with a focus on early detection of cervical cancer. Roche will pay MTM shareholders approximately $185 million up front and up to $85 million in milestone payments. MTM’s test is based on the p16 biomarker, a gene involved in tumor suppression. The amount of p16 increases after persistent human papillomavirus (HPV) infection leads to oncogenic transformations of cells in the cervix. Roche says MTM’s products complement its Cobas HPV assay for cervical cancer screening, launched last year.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter